Skip to main content
Journal cover image

Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.

Publication ,  Journal Article
Park, KS; Bazzill, JD; Son, S; Nam, J; Shin, SW; Ochyl, LJ; Stuckey, JA; Meagher, JL; Chang, L; Song, J; Montefiori, DC; LaBranche, CC; Xu, J ...
Published in: J Control Release
February 10, 2021

The current health crisis of corona virus disease 2019 (COVID-19) highlights the urgent need for vaccine systems that can generate potent and protective immune responses. Protein vaccines are safe, but conventional approaches for protein-based vaccines often fail to elicit potent and long-lasting immune responses. Nanoparticle vaccines designed to co-deliver protein antigens and adjuvants can promote their delivery to antigen-presenting cells and improve immunogenicity. However, it remains challenging to develop vaccine nanoparticles that can preserve and present conformational epitopes of protein antigens for induction of neutralizing antibody responses. Here, we have designed a new lipid-based nanoparticle vaccine platform (NVP) that presents viral proteins (HIV-1 and SARS-CoV-2 antigens) in a conformational manner for induction of antigen-specific antibody responses. We show that NVP was readily taken up by dendritic cells (DCs) and promoted DC maturation and antigen presentation. NVP loaded with BG505.SOSIP.664 (SOSIP) or SARS-CoV-2 receptor-binding domain (RBD) was readily recognized by neutralizing antibodies, indicating the conformational display of antigens on the surfaces of NVP. Rabbits immunized with SOSIP-NVP elicited strong neutralizing antibody responses against HIV-1. Furthermore, mice immunized with RBD-NVP induced robust and long-lasting antibody responses against RBD from SARS-CoV-2. These results suggest that NVP is a promising platform technology for vaccination against infectious pathogens.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Control Release

DOI

EISSN

1873-4995

Publication Date

February 10, 2021

Volume

330

Start / End Page

529 / 539

Location

Netherlands

Related Subject Headings

  • Viral Vaccines
  • SARS-CoV-2
  • Rabbits
  • Pharmacology & Pharmacy
  • Nanoparticles
  • Mice, Inbred BALB C
  • Mice
  • Lymph Nodes
  • Lipids
  • Immunity, Humoral
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Park, K. S., Bazzill, J. D., Son, S., Nam, J., Shin, S. W., Ochyl, L. J., … Moon, J. J. (2021). Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. J Control Release, 330, 529–539. https://doi.org/10.1016/j.jconrel.2020.12.031
Park, Kyung Soo, Joseph D. Bazzill, Sejin Son, Jutaek Nam, Seung Won Shin, Lukasz J. Ochyl, Jeanne A. Stuckey, et al. “Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.J Control Release 330 (February 10, 2021): 529–39. https://doi.org/10.1016/j.jconrel.2020.12.031.
Park KS, Bazzill JD, Son S, Nam J, Shin SW, Ochyl LJ, et al. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. J Control Release. 2021 Feb 10;330:529–39.
Park, Kyung Soo, et al. “Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.J Control Release, vol. 330, Feb. 2021, pp. 529–39. Pubmed, doi:10.1016/j.jconrel.2020.12.031.
Park KS, Bazzill JD, Son S, Nam J, Shin SW, Ochyl LJ, Stuckey JA, Meagher JL, Chang L, Song J, Montefiori DC, LaBranche CC, Smith JL, Xu J, Moon JJ. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. J Control Release. 2021 Feb 10;330:529–539.
Journal cover image

Published In

J Control Release

DOI

EISSN

1873-4995

Publication Date

February 10, 2021

Volume

330

Start / End Page

529 / 539

Location

Netherlands

Related Subject Headings

  • Viral Vaccines
  • SARS-CoV-2
  • Rabbits
  • Pharmacology & Pharmacy
  • Nanoparticles
  • Mice, Inbred BALB C
  • Mice
  • Lymph Nodes
  • Lipids
  • Immunity, Humoral